The Payer Exchange Podcast Episode 11: USA Special - Jill Hanson

Series 3 of The Payer Exchange takes a vacation to the United States, but with a global question in mind: how might changing US pricing policy affect market access, launch strategy and patient access elsewhere?

In the opening episode, Omar Ali speaks with Jill Hanson, VP of Regional Pharmacy at Centene Pharmacy Services, who brings a specialty pharmacy perspective to changes in drug pricing, contracting and medical benefit management, from one of the largest Medicaid managed care organisations in the US. 

Jill’s discussion is grounded in practical payer operations: how formulary and contracting strategies may evolve as reliance on rebate maximisation reduces, how plans forecast high-cost therapies, and how medical benefit management and site-of-care optimisation can create value beyond unit price.

Key themes:

  • MFN, GUARD and GLOBE: implications for formulary and contracting strategy

  • Moving from rebate maximisation towards value-based agreement

  • Forecasting high-cost therapies and the potential for more dynamic pricing

  • Part B / MFP impacts on provider reimbursement and medical benefit management

  • Site-of-care optimisation and patient-centred delivery

What I can say in terms of expectations from a commercial standpoint is that formulary and contracting strategies need to evolve with less reliance on rebate maximization.
— Jill Hanson

About The Payer Exchange

The Payer Exchange is a podcast from Verpora exploring the people, policies and decisions shaping pharmaceutical market access around the world. Hosted by Omar Ali, Verpora’s Head of Payers, each episode features an in-depth one-to-one conversation with payers, policy experts and healthcare leaders, offering direct insight into pricing, reimbursement, access and the practical pressures shaping healthcare systems and pharmaceutical strategy.

Disclaimer: This presentation is for educational and informational purposes only, and is not intended as legal or policy advice. This presentation is based on non-confidential intelligence. Views expressed by the speakers are personal opinions and should not be attributed to anyone else or any organization. No part of this presentation may be reproduced for commercial purposes without the express permission of Verpora.

Next
Next

Webinar: Improving Forecast Accuracy for High-Cost Oncology Medicines – What NHS Oncology Pharmacy Operations Reveal About Real-World Utilisation